During the past 20 years, the history and development of infectious disease genomics are tightly associated with the Human Genome Project (HGP). It has been emphasized since the beginning of the HGP that such effort must not be restricted to the human genome and should include other organisms including mouse, bacteria, yeast, fruit fly, and worm for comparative sequence analyses. A brief history is reviewed in this chapter. Currently, nearly 6000 genome sequencing projects have been reported. The majority of the more than 1000 completed genomes are bacterial sequences (\>80%). An important motivation for these efforts is to develop preventative, diagnostic, and therapeutic strategies through the analysis of sequenced microorganisms, parasites, and vectors related to human health. A few examples are discussed in this chapter.

10.1. Introduction {#s0010}
==================

The history and development of infectious disease genomics are tightly associated with the Human Genome Project (HGP) ([@bib93]). A series of important discussions about the HGP were made in 1985 and 1986 ([@bib25], [@bib93]), which led to the appointment of a special National Research Council (NRC) committee by the National Academy of Sciences to address the needs and concerns, such as its impact, leadership, and funding sources. The committee recommended that the United States begin the HGP in 1988 ([@bib71]). They emphasized the need for technological improvements in the efficiency of gene mapping, sequencing, and data analysis capabilities. In order to understand potential functions of human genes through comparative sequence analyses, they also advised that the HGP must not be restricted to the human genome and should include model organisms including mouse, bacteria, yeast, fruit fly, and worm. In the meantime, the Office of Technology Assessment (OTA) of the US Congress also issued a similar report to support the HGP ([@bib72]). In 1990, the Department of Energy (DOE) and the National Institutes of Health (NIH) jointly presented an initial 5-year plan for the HGP ([@bib23]). In October 1993, the Sanger Center/Institute (Hinxton, UK) was officially open to join the HGP. The cost of DNA sequencing was about \$2--5 per base in 1990, and the initial aim was to reduce the costs to less than \$0.50 per base before large-scale sequencing ([@bib23]). The sequencing cost gradually declined during the subsequent years. In 2004, the National Human Genome Research Institute (NHGRI) challenged scientists to achieve a \$100,000 human genome (3 Gb/haploid genome) by 2009 and a \$1000 genome by 2014 to meet the need of genomic medicine.

The first complete genome to be sequenced was the phiX174 bacteriophage (5.4 kb) by Sanger's group in 1977 ([@bib82]). The complete genome sequence of SV40 polyomavirus (5.2 kb) was published in 1978 ([@bib34], [@bib77]). The human Epstein--Barr virus (170 kb) genome was determined in 1984 ([@bib4]). The first completed free-living organism genome was *Haemophilus influenza* (1.8 Mb), sequenced through a whole-genome shotgun approach in 1995 ([@bib36]). The second sequenced bacterial genome, *Mycoplasma genitalium* (600 kb), was completed in less than a month in the same year using the same approach ([@bib87]). The DOE was the first to start a microbial genome program (MGP) as a companion to its HGP in 1994 ([@bib24]). The initial focus was on nonpathogenic microbes. Along with the development of the HGP, there was exponential growth of the number of completely sequenced free-living organism genomes. The Fungal Genome Initiative (FGI) ([@bib33]) was established in 2000 to accelerate the slow pace of fungal genome sequencing since the report of the genome of *Saccharomyces cerevisiae* in 1996 ([@bib40]). One of the major interests was to sequence organisms that are important in human health and commercial activities. As of September 2009, 1100 completed genome projects, a 1.7-fold increase from 2 years ago, were documented ([@bib57]). These include 914 bacterial, 68 archaeal, and 118 eukaryotic genomes. In addition, more than 4000 other ongoing sequencing projects were reported.

The genomes of human malaria parasite *Plasmodium falciparum* and its major mosquito vector *Anopheles gambiae* were published in 2002 ([@bib37], [@bib44]). The effort to sequence the malaria genome began in 1996 by taking advantage of a clone derived from laboratory-adapted strain ([@bib43]). Many parasites have complex life cycles that involve both vertebrate and invertebrate hosts and are difficult to maintain in the laboratory. Currently, a few other important human pathogenic parasites, such as Trypansomes ([@bib9], [@bib28]), Leishmania ([@bib47]), and Schistosomas ([@bib10], [@bib18]), have been either completely or partially sequenced ([@bib14], [@bib3]). In the meantime, the genome sequence of *Aedes aegypti*, the primary vector for yellow fever and dengue fever, was published in 2007 ([@bib70]). The genome size (1376 Mb) of this mosquito vector is about 5 times larger than the previously sequenced genome of the malaria vector *Anopheles gambiae*. Approximately 50% of the genome consists of transposable elements. In 2010, the genome sequence of the body louse (*Pediculus humanus humanus*), an obligatory parasite of humans and the main vector of epidemic typhus (*Rickettsia prowazekii*), relapsing fever (*Borrelia recurrentis*), and trench fever (*Bartonella quintana*), was reported ([@bib53]). Its 108 Mb genome is the smallest among the known insect genomes. Genome sequencing projects for other important human disease vectors are in progress ([@bib55], [@bib66]). These include *Culex pipiens* (mosquito vector of West Nile virus), *Ixodes scapularis* (tick vector of Lyme disease, babesia, and anaplasma), and *Glossina morsitans* (tsetse fly vector of African trypanosomiasis). The challenge to sequence the genome of an insect vector is much greater than a microbe. For example, the genomes of ticks were estimated to be between 1 and 7 Gb and may have a significant proportion of repetitive DNA sequences, which may be a problem for genome assembly ([@bib73]). Furthermore, the evolutionary distances among insect species may also affect homology-based gene predictions.

It is as important to understand the sequence diversity within a species as to perform a de novo sequencing of a reference genome from the perspective of human health. This is true for both hosts and pathogens ([@bib31], [@bib1]). The goal of the 1000 Genomes Project is to find most genetic variants that have frequencies of at least 1% in the human populations studied ([@bib51]). One of the similar efforts for human pathogens is the NIH Influenza Genome Sequencing Project. When this project began in November 2004, only seven human influenza H3N2 isolates had been completely sequenced and deposited in the GenBank database ([@bib30], [@bib38]). As of May 2010, more than 5000 human and avian isolates have been completely sequenced, including the 1918 "Spanish" influenza virus ([@bib88]). Databases for human immunodeficiency virus (HIV) and hepatitis C virus have also been established.

While most human studies of microbes have focused on the disease-causing organisms, interest in resident microorganisms has also been growing. In fact, it has been estimated that the human body is colonized by at least 10 times more prokaryotic and eukaryotic microorganisms than the number of human cells ([@bib83]). It was suggested to have "the second human genome project" to sequence human microbiome ([@bib78]). Highly variable intestinal microbial flora among normal individuals has been well documented ([@bib26], [@bib19], [@bib90]). Therefore, the Human Microbiome Project (HMP) was initiated by the NIH to study samples from multiple body sites from each of at least 250 "normal" volunteers to determine whether there are associations between changes in the microbiome and several different medical conditions, and to provide both standardized data resources and new technological approaches ([@bib74]).

The completed or ongoing genome projects ([Table 10.1](#t0010){ref-type="table"} ) will provide enormous opportunities for the discovery of novel vaccines and drug targets against human pathogens as well as the improvement of diagnosis and discovery of infectious agents and the development of new strategies for invertebrate vector control. Specific examples will be provided to illustrate how the information provided by various genome projects may help achieve the goal of promoting human health.Table 10.1The Completed or Ongoing Genome Projects*General*NCBI ([@bib84]) (<http://www.ncbi.nlm.nih.gov/sites/genome>)ENSEMBL ([@bib52]) (<http://www.ensemblgenomes.org/>)JCVI ([@bib21]) ([http://cmr.jcvi.org/](http://www.cmr.jcvi.org/))GOLD ([@bib57]) (<http://www.genomesonline.org>)Sanger Pathogen Genomics (<http://www.sanger.ac.uk/Projects/Pathogens/>)GeMInA (Genomic Metadata for Infectious Agents) ([@bib27], [@bib85]) ([http://gemina.igs.umaryland.edu](http://www.gemina.igs.umaryland.edu))*Bacteria*HMP ([@bib69]) (<http://www.hmpdacc.org/>)*Fungi*FGI (<http://www.broadinstitute.org/science/projects/fungal-genome-initiative>)*Parasites*Eukaryotic pathogens ([@bib3]) ([http://EuPathDB.org](http://www.EuPathDB.org))Parasite genome projects (<http://www.pasteur.fr/recherche/unites/tcruzi/minoprio/genomics/parasites.htm>)*Invertebrate vectors*VectorBase ([@bib55], [@bib66]) (<http://www.vectorbase.org>)*Viruses*Influenza virus ([@bib7]) (<http://www.ncbi.nlm.nih.gov/genomes/FLU/>)HIV (<http://www.hiv.lanl.gov/>)HCV ([http://hcv.lanl.gov/](http://www.hcv.lanl.gov/))

10.2. Vaccine Target {#s0015}
====================

Meningococcal isolates produce 1 of 13 antigenically distinct capsular polysaccharides, but only 5 (A, B, C, W135, and Y) are commonly associated with disease ([@bib59]). The polysaccharide capsule is important for meningococci to escape from complement-mediated killing. While conventional vaccines consisting of the conjugation of capsular polysaccharides to carrier proteins for meningococcus serogroups A, C, Y, and W-135 have been clinically successful, the same approach failed to produce clinically useful vaccine for serogroup B (MenB). The capsule polysaccharide (α2-8 *N*-acetylneuraminic acid) of MenB is identical to human polysialic acid and therefore is poorly immunogenic ([@bib35]). Alternatively, vaccines consisting of outer membrane vesicles (OMV) have been successfully developed to control MenB outbreaks in areas where epidemics are dominated by one particular strain ([@bib11], [@bib86], [@bib13], [@bib48]). The most significant limitation of this type of vaccine is that the immune response is strain-specific, mostly directed against the porin protein, PorA, which varies substantially in both expression level and sequence across strains ([@bib65], [@bib75]).

With the completion of the genome sequence of a virulent MenB strain, a "reverse vaccinology" approach was applied for the development of a universal MenB vaccine by Novartis ([@bib75], [@bib89], [@bib39]). Through bioinformatic searching for surface-exposed antigens, which may be the most suitable vaccine candidates due to their potential to be readily recognized by the immune system, 570 open reading frames (ORFs) were selected from a total of 2158 ORFs of the MC58 genome. Eventually, five antigens were chosen as the vaccine components based on a series of criteria including the ability of candidates to be expressed in *Escherichia coli* as recombinant proteins (350 candidates), the confirmation of surface exposure by immunological analyses, the ability of induced protective antibodies in experimental animals (28 candidates), and the conservation of antigens within a panel of diverse meningococcal strains, primarily the disease-associated MenB strains ([@bib75], [@bib39], [@bib80]). The vaccine formulation consists of an fHBP-GNA2091 fusion protein, a GNA2132-GNA1030 fusion protein, NadA, and OMV from the New Zealand MeNZB vaccine strain, which contains the immunogenic PorA. Initial phase II clinical results in adults and infants showed that this vaccine could induce a protective immune response against three diverse MenB strains in 89--96% of subjects following three vaccinations and 93--100% after four vaccinations ([@bib80]). In 2010, a phase III trial for this vaccine (4CMenB) has met primary endpoint.

10.3. Drug Target {#s0020}
=================

Targeting an essential pathway is a necessary but not sufficient requirement for an effective antimicrobial agent ([@bib15]). Identification of essential genes in a completely sequenced genome has been actively pursued with various approaches ([@bib45], [@bib49]). The indispensable fatty acid synthase (FAS) pathway in bacteria has been regarded as a promising target for the development of antimicrobial agents ([@bib94]). The subcellular organization of the fatty acid biosynthesis components is different between mammals (type I FAS) and bacteria (dissociated type II FAS), which raises the likelihood of host specificity of the targeting drugs. Comparison of the available genome sequences of various species of prokaryotes reveals highly conserved FAS II systems suggesting that the antimicrobial agent can be broad spectrum ([@bib95]). In addition, through computational analyses, new members of the FAS II system have been discovered in different bacterial species ([@bib42], [@bib63]). One of the protein components in this system, FabI, is the target of an anti-tuberculosis drug isoniazid and a general antibacterial and antifungal agent, triclosan ([@bib6], [@bib56], [@bib96]).

Through a systematic screening of 250,000 natural product extracts, a Merck team identified a potent and broad-spectrum antibiotic, platensimycin, which is derived from *Streptomyces platensis* and a selective FabF/B inhibitor in FAS II system ([@bib92]). Treatment with platensimycin eradicated *Staphylococcus aureus* infection in mice. Platensimycin did not have cross-resistance to other antibiotic-resistant strains in vitro, including methicillin-resistant *S. aureus*, vancomycin-intermediate *S. aureus*, and vancomycin-resistant enterococci. No toxicity was observed using a cultured human cell line. The activity of platensimycin was not affected by the presence of human serum in this study. However, the FAS II system appears to be dispensable for another Gram-positive bacterium, *Streptococcus agalactiae*, when exogenous fatty acids are available, such as in human serum ([@bib15], [@bib5]). The susceptibility to inhibitors targeting the FAS II system indicates heterogeneity in fatty acid synthesis or in acquiring exogenous fatty acids among Gram-positive pathogens ([@bib5]). Comparative genomic approaches may be useful to identify and develop a strategy to target the salvage pathway for *Streptococcus agalactiae*. Alternatively, similar approaches as described earlier for MenB vaccine may also be applied for *Streptococcus agalactiae* (Group B streptococcus) ([@bib62]).

10.4. Vector Control {#s0025}
====================

An early mathematical model for malaria control suggested that the most vulnerable element in the malaria cycle was survivorship of adult female mosquitoes ([@bib61], [@bib29]). Therefore, insect control is an important part of reducing transmission. The use of DDT as an indoor residual spray in the global malaria eradication program from 1957 to 1969 reduced the population at risk of malaria to ∼50% by 1975 compared with 77% in 1900 ([@bib41], [@bib29]). Engineering genetically modified mosquitoes refractory to malaria infection appeared to be an alternative approach ([@bib20]) given the environmental impact of DDT and the emergence of insecticide-resistant insects. The Vector Biology Network (VBN) was formed in 1989 and proposed a 20-year plan with the World Health Organization (WHO) in 2001 to achieve three major goals: (1) to develop basic tools for the stable transformation of anopheline mosquitoes by the year 2000; (2) to engineer a mosquito incapable of carrying the malaria parasite by 2005; and (3) to run controlled experiments to test how to drive the engineered genotype into wild mosquito populations by 2010 ([@bib2], [@bib67], [@bib8]). While some proof-of-concept experiments were achieved for the first two aims in 2002 when the *Anopheles gambiae* genome was completely sequenced ([@bib16], [@bib46]), the progress has been relatively slow ([@bib64]).

Genomic loci of the *Anopheles gambiae* responsible for *Plasmodium falciparum* resistance have been identified through surveying a mosquito population in a West African malaria transmission zone ([@bib79]). A candidate gene, Anopheles Plasmodium-responsive leucine-rich repeat 1 (*APL1*), was discovered. Subsequently, other resistant genes have also been identified ([@bib12], [@bib76]). Studying the genetic basis of resistance to malaria parasites and immunity of the mosquito vector will be important to control malaria transmission.

10.5. Diagnostic Target and Pathogen Discovery {#s0030}
==============================================

Perhaps the most immediate impact of a completely sequenced pathogen genome is for infectious disease diagnosis. The information may be of great importance to the public health when a newly emerged or re-emerged pathogen is discovered. The 2009 swine-origin influenza A virus (S-OIV) ([@bib22]) and 2003 SARS (severe acute respiratory syndrome) coronavirus ([@bib54], [@bib81]) are the two most recent examples.

S-OIV emerged in the spring of 2009 in Mexico and was also discovered in specimens from two unrelated children in the San Diego area in April 2009 ([@bib17], [@bib22]). Those samples were positive for influenza A but negative for both human H1 and H3 subtypes. The complete genome sequence and a real-time PCR-based diagnostic assay were released to the public in late April. The outbreak evolved rapidly and the WHO declared the highest Phase 6 worldwide pandemic alert on June 11, 2009. S-OIV has three genome segments (HA, NP, NS) from the classic North American swine (H1N1) lineage, two segments (PB2, PA) from the North American avian lineage, one segment (PB1) from the seasonal H3N2, and most notably, two segments (NA, M) from the Eurasian swine (H1N1) lineage ([@bib22]). With the available influenza genome database, diagnostic assays to distinguish previous seasonal H1N1, H3N2, and S-OIV can be easily accomplished ([@bib60]).

A comprehensive pathogen genome database is not only useful for infectious disease diagnosis but also for novel pathogen discovery ([@bib58]). Homologous sequences within the same family or among different family members are important for new pathogen identification even with the advent of third-generation sequencing technology ([@bib68]). De novo pathogen discovery may be also complicated by coexisting microorganisms, such as commensal bacteria in the human body. Without prior knowledge of these microorganisms, one may be misled.

In 2003, a microarray-based assay, designated Virochip, was used to help discover the SARS coronavirus ([@bib91]). The Virochip contained the most highly conserved 70mer sequences from every fully sequenced reference viral genome in GenBank. The computational search for conservation was performed across all known viral families. A microarray hybridized with a reaction derived from a viral isolate cultivated from a SARS patient revealed that the strongest hybridizing array elements belong to families Astroviridae and Coronaviridae. Alignment of the oligonucleotide probes having the highest signals showed that all four hybridizing oligonucleotides from the Astroviridae and one oligonucleotide from avian infectious bronchitis virus, an avian coronavirus, shared a core consensus motif spanning 33 nucleotides. Interestingly, it had been known previously through bioinformatic analyses that this sequence is present in the 3′ UTR of all astroviruses, avian infectious bronchitis virus, and an equine rhinovirus ([@bib50]). Therefore, a new member of the coronavirus was identified through the unique hybridizing pattern and subsequent confirmations.

The finding of the seventh human oncogenic virus, Merkel cell polyomavirus (MCV) ([@bib32]) in 2008 is another example of why conserved sequences are important for novel pathogen discovery. MCV is the etiological agent of Merkel cell carcinoma (MCC), which is a rare but aggressive skin cancer of neuroendocrine origin. Two cDNA libraries derived from MCC tumors were subjected to high-throughput sequencing by a next-generation Roche/454 sequencer. Nearly 400,000 sequence reads were generated. The majority (99.4%) of the sequences derived from human origin were removed from further analyses. Only one of the remaining 2395 cDNA was homologous to the T antigen of two known polyomaviruses. One additional cDNA was subsequently identified to be part of the MCV sequence when the complete viral sequence was known. Later analyses showed that 80% (8/10) of the MCC had integrated MCV in the human genome. Monoclonal viral integration was revealed by the patterns of Southern blot analysis. Only 8--16% of control tissues had low copy number of MCV infection.

10.6. Conclusion {#s0035}
================

While we can expect that the efforts of a variety of genome projects may improve human health, the socioeconomic issues that are not discussed in this chapter may be substantial. In addition, the tremendous amount of information derived from these projects will also be a challenge for scientists as well nonscientists to follow and understand.
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